{"id":857,"date":"2026-03-30T15:55:45","date_gmt":"2026-03-30T14:55:45","guid":{"rendered":"https:\/\/www.aescap.com\/?page_id=857"},"modified":"2026-05-05T14:59:22","modified_gmt":"2026-05-05T13:59:22","slug":"aescap-genetics-fonds","status":"publish","type":"page","link":"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/","title":{"rendered":"Aescap Genetics Fonds"},"content":{"rendered":"<div class=\"block\" id=\"Aescap-Life-Sciences-Fonds\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">beleggen in Aescap Genetics<\/span>\n                    <h2>Ondernemingen die de geneeskunde vooruitbrengen<\/h2>\n                    <p>Het Aescap Genetics Fonds bestaat sinds begin 2022. Het is een open-end fonds waarbij u wekelijks kunt in- en uittreden. Het belegt in beursgenoteerde biotechbedrijven die nieuwe genetische medische behandelingen ontwikkelen en op de markt brengen, zoals gen-, RNA- en celtherapie\u00ebn. Het voordeel van Genetics-medicijnen is dat ze de oorzaak van ziektes aanpakken en niet enkel de symptomen.<\/p>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/doctor-touches-creative-glowing-medical-interface-2026-01-11-08-40-40-utc-scaled.jpg\" alt=\"Ondernemingen die de geneeskunde vooruitbrengen\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<section class=\"section highlight-section\">\n  <div class=\"container highlight-content\">\n    <div class=\"reveal\">\n              <span class=\"section-label\" style=\"color: var(--light-blue);\">Fondsgegevens<\/span>\n                          <p>Het Aescap Genetics Fonds belegt in een geconcentreerd portfolio van circa 20 beursgenoteerde biotech- en life sciences bedrijven.<\/p>\n          <\/div>\n\n          <div class=\"stats-grid\">\n                              <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">\u00b120<\/div>\n              <div class=\"stat-label\">Bedrijven in portfolio<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-2\">\n              <div class=\"stat-number\">\u20ac40M<\/div>\n              <div class=\"stat-label\">AUM &#8211; Max. fundsize \u20ac300M<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">+20%<\/div>\n              <div class=\"stat-label\">Rendementsdoelstelling netto per jaar op middellange termijn<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">+21,4%<\/div>\n              <div class=\"stat-label\">Rendement in 2025<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-2\">\n              <div class=\"stat-number\">+29%*<\/div>\n              <div class=\"stat-label\">Outperformance vs. JPMorgan Genetic Therapies Fund Benchmark (in EUR)<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">+1,5%<\/div>\n              <div class=\"stat-label\">Net IRR sinds 19 januari 2022<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">1,44% | 17%**<\/div>\n              <div class=\"stat-label\">Management fee | Performance Fee<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-2\">\n              <div class=\"stat-number\">0,0% | 0,2%<\/div>\n              <div class=\"stat-label\">Entry fee | Exit fee<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">2,06%<\/div>\n              <div class=\"stat-label\">Total cost ratio (verwachting 2026)<\/div>\n            <\/div>\n                        <\/div>\n    \n          <div class=\"highlight-actions reveal reveal-delay-3\">\n                  <a href=\"https:\/\/www.aescap.com\/nl\/rendement\/#rendement_genetics\" class=\"btn-primary\" >\n            Volledig overzicht Performance &amp; NAV            <span class=\"arrow\">&rarr;<\/span>\n          <\/a>\n                      <\/div>\n    \n          <div class=\"reveal reveal-delay-3\" style=\"margin-top: 2.5rem;\">\n        <p style=\"font-size: 0.95rem; color: rgba(255, 255, 255, 0.5); max-width: 600px; line-height: 1.7;\">* Van de start van het fonds in 2022 tot 1-1-2026.\r\n** Bij bedragen boven 10M gelden lagere fees<\/p>\n      <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section\" id=\"LS-Beleggingsstrategie\" style=\"background: var(--off-white);\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Beleggingsstrategie<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Focus &amp; discipline<\/h2>\n                    <p style=\"font-size: 1.05rem; color: var(--gray-600); max-width: 600px; font-weight: 400; line-height: 1.8; margin-bottom: 1rem;\">Het Aescap Genetics Fonds wordt actief beheerd op basis van &#039;high conviction&#039;, op basis van uitgebreide fundamentele analyses gecombineerd met intensieve interactie met management en relevante experts.<\/p>\n          <\/div>\n          <div class=\"reasons-grid reasons-grid--cols-3\">\n                  <div class=\"reason-card reveal reveal-delay-1\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><line x1=\"18\" y1=\"20\" x2=\"18\" y2=\"10\"\/><line x1=\"12\" y1=\"20\" x2=\"12\" y2=\"4\"\/><line x1=\"6\" y1=\"20\" x2=\"6\" y2=\"14\"\/><\/svg>              <\/div>\n                        <h3>Groeipotentieel<\/h3>\n            <p>Selectie op basis van &#039;future earning power&#039;, sterk management en beperkt risico. Voorkeur voor bedrijven met geneesmiddelen op de markt \u00e9n een brede pijplijn met onderscheidende geneesmiddelkandidaten.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-2\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><circle cx=\"11\" cy=\"11\" r=\"8\"\/><path d=\"m21 21-4.35-4.35\"\/><path d=\"M11 8v6\"\/><path d=\"M8 11h6\"\/><\/svg>              <\/div>\n                        <h3>Technologieplatforms<\/h3>\n            <p>Voorkeur voor bedrijven met een technologieplatform dat meerdere ziektegebieden kan adresseren en een deel daarvan uit-licenseert t.b.v. extra inkomsten via mijlpaalbetalingen en royalty&#039;s.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-3\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M20 21v-2a4 4 0 0 0-4-4H8a4 4 0 0 0-4 4v2\"\/><circle cx=\"12\" cy=\"7\" r=\"4\"\/><\/svg>              <\/div>\n                        <h3>Discipline<\/h3>\n            <p>Discipline in aandelenselectie, constante monitoring en een aan- en verkoop. De volatiliteit van biotechaandelen cre\u00ebert buy-low\/sell-high kansen voor een ervaren fondsbeheerder.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-1\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z\"\/><\/svg>              <\/div>\n                        <h3>Diversificatie &amp; Risicobeheer<\/h3>\n            <p>Gebalanceerd portfolio, gediversifieerd over ziektegebieden, technologie\u00ebn, geografie\u00ebn en ontwikkelfases. Max. 25% van AUM in high risk \/ high return posities. Rebalancing op basis van target price versus actuele koers.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-2\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M22 11.08V12a10 10 0 1 1-5.93-9.14\"\/><polyline points=\"22 4 12 14.01 9 11.01\"\/><\/svg>              <\/div>\n                        <h3>Waardering<\/h3>\n            <p>Wij berekenen, speculeren niet. Elke onderneming wordt gewaardeerd op basis van een discounted cash flow, gevoed door proprietary field research.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reason-card--dark reveal reveal-delay-3\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z\"\/><polyline points=\"22,6 12,13 2,6\"\/><\/svg>              <\/div>\n                        <h3>Meer weten over onze strategie?<\/h3>\n            <p>In een gesprek komt u direct alles te weten over de strategie van het fonds.<\/p>\n                          <a href=\"mailto:service@aescap.com?subject=Ik%20kom%20graag%20meer%20te%20weten%20over%20de%20beleggingsstrategie%20van%20Aescap%20Genetics\" class=\"block-link\" target=\"_blank\">\n                Stuur een mail aan ons team                <span>&rarr;<\/span>\n              <\/a>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section\" id=\"LS-Beleggingsstrategie\" style=\"background: var(--off-white);\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Competitive edge<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Wat ons onderscheidt<\/h2>\n          <\/div>\n          <div class=\"vacatures-grid\">\n                  <div class=\"vacature-card reveal reveal-delay-1\">\n            <h4>Clinical trial expertise<\/h4>\n            <p>Zeer ervaren in het beoordelen van klinische studiedata en het vertalen ervan naar omzetpotentieel.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-2\">\n            <h4>AI &amp; Data Science<\/h4>\n            <p>Dedicated team van AI-engineers dat data-gedreven inzichten levert voor investeringsbeslissingen.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-3\">\n            <h4>Management dialogue<\/h4>\n            <p>In constant dialoog met het management van portfoliobedrijven: private equity-mentaliteit in een publieke markt.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-4\">\n            <h4>Skin in the game<\/h4>\n            <p>Het investment team heeft meer dan \u20ac10 miljoen in het fonds ge\u00efnvesteerd.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-1\">\n            <h4>Volatiliteit als kans<\/h4>\n            <p>Lage correlatie en hoge volatiliteit van biotechaandelen cre\u00ebren ideale buy-low\/sell-high mogelijkheden.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-2\">\n            <h4>Medisch netwerk<\/h4>\n            <p>Toegang tot artsen, zorgverzekeraars, pati\u00ebnten en ervaren portfolio advisors voor medisch-wetenschappelijke diepgang.<\/p>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n\n<div class=\"block reverse\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Risico&#039;s<\/span>\n                          <h2>Risico\u2019s<\/h2>\n<p>Om de beleggingsrisico\u2019s tot een minimum te beperken, spreidt het fonds zijn portefeuille over verschillende ziekten, verschillende stadia van bedrijfsontwikkeling en verschillende geografische gebieden. Het fonds identificeert een aantal risico\u2019s voor beleggers:<\/p>\n<ul>\n<li><strong>Liquiditeitsrisico<\/strong>: het kan voorkomen dat een door een ingenomen positie niet tijdig tegen een redelijke prijs kan worden geliquideerd vanwege gebrek aan liquiditeit (onvoldoende vraag) in de markt.<\/li>\n<li><strong>Sectorrisico<\/strong>: het fonds investeert in een sector die gekenmerkt wordt door een hoge beweeglijkheid waarbij een actieve beleggingsaanpak zeer belangrijk is. Dit kan een positieve of negatieve impact hebben op de waarde van het fonds.<\/li>\n<li><strong>Valutarisico<\/strong>: het fonds dekt valutaposities in beginsel niet af. Beleggingen anders dan in euro\u2019s kunnen hierdoor fluctuaties in de netto vermogenswaarde van het fonds, zowel positief als negatief, veroorzaken.<\/li>\n<\/ul>\n<p>Voor het overzicht van ge\u00efdentificeerde risico\u2019s verwijzen we naar de\u00a0<a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/10\/241004-Aescap-Genetics-Prospectus-.pdf\" target=\"_blank\" rel=\"noopener\">prospectus die u op deze pagina kunt downloaden.<\/a><\/p>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/AFM-risico-icoon_6_NL.png\" alt=\"\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<div class=\"block\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Vertrouwd<\/span>\n                    <h2>Governance &amp; Toezicht<\/h2>\n                    <p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">De beheerder van de fondsen, Privium Fund Management BV, staat onder toezicht van de AFM en DNB en werkt uitsluitend samen met onafhankelijke, gespecialiseerde partijen voor bewaring en administratie.<\/p>\n<ul class=\"[li_&amp;]:mb-0 [li_&amp;]:mt-1 [li_&amp;]:gap-1 [&amp;:not(:last-child)_ul]:pb-1 [&amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\">\n<li class=\"whitespace-normal break-words pl-2\"><strong>Bewaarder:<\/strong> Apex Depositary Services \u2014 verantwoordelijk voor de onafhankelijke bewaring van de fondsactiva.<\/li>\n<li class=\"whitespace-normal break-words pl-2\"><strong>Administrateur:<\/strong> IQEQ Financial Services \u2014 verantwoordelijk voor de onafhankelijke fondadministratie en NAV-berekening.<\/li>\n<li><strong>Accountant:<\/strong> Forvis Mazars N.V. \u2014 verantwoordelijk voor de onafhankelijke controle van de jaarrekening.<\/li>\n<\/ul>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/04\/Parties-involved-2-scaled.png\" alt=\"Governance &amp; Toezicht\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<div class=\"block reverse\" id=\"LS-Duurzaamheid\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Samenvatting Aescap Genetics<\/span>\n                    <h2>Duurzaamheidsgerelateerde informatie en disclosures<\/h2>\n                    <p>Aescap Genetics (het\u00a0<strong>Fonds<\/strong>) heeft als doel waarde te cre\u00ebren door te beleggen in beursgenoteerde aandelen van biotechnologische ondernemingen met een specialisatie in genetica. Het Fonds investeert in innovatieve ondernemingen die nieuwe genetische medische behandelingen ontwikkelen en op de markt brengen, zoals gen-, RNA- en celtherapie\u00ebn. Het Fonds kan in beperkte mate ook beleggen in ondernemingen die medische genetische diagnostiek ontwikkelen en op de markt brengen. Het Fonds streeft naar een gemiddeld jaarlijks nettorendement (na aftrek van kosten) van minimaal 20 procent over 4-5 jaar. Het Fonds zal doorgaans investeren in bedrijven met het potentieel om hun aandelenprijs (meer dan) te verdubbelen over dezelfde periode.<\/p>\n                    <button class=\"show-more-toggle\" type=\"button\" aria-expanded=\"false\">\n          Lees meer          <span class=\"show-more-chevron\">&#9662;<\/span>\n        <\/button>\n        <div class=\"show-more-content\">\n          <p>Naast het doel om een financieel rendement voor investeerders te behalen, bevordert het Fonds ook een sociaal kenmerk en is derhalve geclassificeerd onder artikel 8 van de\u00a0<em>Sustainable Finance Disclosure Regulation<\/em>\u00a0(<strong>SFDR<\/strong>). De investeringen van het Fonds zijn voornamelijk gericht op het onderzoek naar, de ontwikkeling van of de productie van behandelingen\/oplossingen voor ziekten met een hoge onvervulde medische behoefte. Een hoge onvervulde medische behoefte is gedefinieerd als ziekten die worden gekenmerkt door een (ontoereikendheid van) beschikbare behandelingen, die ernstige gevolgen hebben voor de pati\u00ebnt en het zorgsysteem, en die voorkomen in de regio\u2019s waar de onderneming momenteel de huidige of toekomstige product(en) op de markt brengt of van plan is te gaan distribueren.<\/p>\n<p>Het Fonds streeft ernaar een portefeuille samen te stellen van ongeveer 18 ondernemingen die bijdragen aan het sociale kenmerk, en waarvan minimaal 30 procent (van het belegd vermogen van het Fonds) als duurzaam wordt beschouwd. Het belegd vermogen bestaat uit het Fondsvermogen, exclusief liquide middelen.<\/p>\n<p>Naast het vaststellen van de duurzaamheidsrisico\u2019s voor iedere investering die materieel worden beschouwd op basis van de\u00a0<em>Sustainability Accounting Standards Board<\/em>\u00a0(<strong>SASB<\/strong>), analyseert het Fonds als onderdeel van het due diligence proces ook de mate waarin de onderneming op deze duurzaamheidsrisico\u2019s is voorbereid. Het Fonds houdt rekening met de\u00a0<em>Principal Adverse Impact<\/em>\u00a0(<strong>PAI<\/strong>) indicatoren om te bepalen of een belegging als duurzaam kan worden beschouwd. Het Fonds onderzoekt de processen en het beleid van iedere (potenti\u00eble) investering op ecologische en sociale risico\u2019s zoals gedefinieerd door de SASB voor de biotechnologie en farmaceutische sector en door de PAI indicatoren.<\/p>\n<p>Het monitoren van investeringen met betrekking tot hun prestaties op ecologisch, sociaal en goed bestuur gebied (<em>Environmental, Social and Governance<\/em>,\u00a0<strong>ESG<\/strong>) vindt maandelijks plaats. Maandelijks wordt er gerapporteerd op de materiele duurzaamheidsrisico\u2019s, het aandeel investeringen van het belegd vermogen dat bijdraagt aan het sociale kenmerk en het aandeel investeringen dat als duurzaam is aangemerkt.<\/p>\n<p>Het Fonds benadert de investeringen om hun ESG-prestaties te verbeteren door zogeheten engagement. Engagement kan bestaan uit overleggen met het management, gegevens verzoeken aan een Investor Relations afdeling, sturing om beleid en de praktijken binnen ondernemingen te verbeteren, of formeel stemmen als aandeelhouder wanneer dat nodig wordt geacht.<\/p>\n<p>Het Fonds rapporteert maandelijks en kwartaallijks over haar financi\u00eble resultaten. Ook publiceert het Fonds jaarlijks een PAI-verslag waarin de engagement activiteiten worden belicht.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.aescap.com\/sustainability\/\" target=\"_blank\" rel=\"noopener\">Summary<\/a>\u00a0(EN)<\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_Summary_DK.pdf\" target=\"_blank\" rel=\"noopener\">Sammenfatning<\/a>\u00a0(DK)<\/li>\n<\/ul>\n        <\/div>\n                    <a href=\"https:\/\/www.aescap.com\/nl\/esg-aescap-genetics-fonds\/\" class=\"block-link\" >\n          Duurzaamheidsinformatie &amp; disclosures          <span>&rarr;<\/span>\n        <\/a>\n          <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/Duurzaam-blauw-scaled.png\" alt=\"Duurzaamheidsgerelateerde informatie en disclosures\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<section class=\"section\" id=\"documenten\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Documenten<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Aescap Genetics Fondsdocumenten<\/h2>\n                    <p style=\"font-size: 1.05rem; color: var(--gray-600); max-width: 700px; font-weight: 400; line-height: 1.8; margin-bottom: 1rem;\">Download de relevante fondsdocumenten van het Aescap Genetics Fonds. Neem contact met ons op als u aanvullende informatie wenst.<\/p>\n          <\/div>\n\n          <div class=\"docs-grid\">\n                  <div class=\"docs-column reveal reveal-delay-1\">\n            <h3>Prospectus<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/10\/241004-Aescap-Genetics-Prospectus-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Prospectus Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/10\/241004-Explanation-updated-prospectus-Aescap-Genetics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Explanation updated Prospectus Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/12\/AescapGen_SUPPL1_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Supplement I to Prospectus Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/12\/AescapGen_EXPL_SUPPL1_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Explanation to Supplement I Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/03\/AescapGen_SUPPL2_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Supplement II to Prospectus Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/03\/AescapGen_EXPL_SUPPL2_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Explanation Supplement II to Prospectus Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      SFDR Pre-contractual disclosure document Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PAI_Statement_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      PAI Report 2024 Aescap Aescap Genetics                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-2\">\n            <h3>Essenti\u00eble-informatiedocumenten<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Genetics \u2013 Investors                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-10M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Genetics \u2013 Investors 10M+                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-20M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Genetics \u2013 Investors 20M+                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-30M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Genetics \u2013 Investors 30M+                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Manager_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Genetics \u2013 Manager                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-3\">\n            <h3>Formulieren<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapGen_SUBFORM_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Subscription form Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapGen_ADDL_SUBFORM_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Additional Subscription form Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-individuals.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      FATCA formulier &#8211; Self-certification form (individuals)                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-Entities.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      FATCA formulier &#8211; Self-certification form (entities)                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-1\">\n            <h3>Financial Reports Aescap Genetics<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/05\/AescapGen_ARPT_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2025 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/08\/AescapGen_SARPT_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2025 Aescap Genetics                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2025\/05\/Aescap-Genetics-Fund-Annual-Report-2024.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2024 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/08\/AESCAP-Genetic-Fund-Semi-Annual-2024.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2024 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/04\/240430-Annual-Report-2023-Aescap-Genetics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2023 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2023\/09\/230817-Interim-Financial-Statements-2023-Aescap-Genetics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2023 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2023\/05\/230430-Annual-Report-2022-Aescap-Genetics-Fund.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2022 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2022\/09\/220801-Interim-Financial-Statements-2022-Aescap-Genetics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2022 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-2\">\n            <h3>Fund Manager &#8211; Privium Fund Management<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_ChamberofCommerce.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Extract Chamber of Commerce                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"#\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Copy of Investment Management licence                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"#\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Confirmation Privium FM Status AIFM                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Remuneration_Policy.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Remuneration Policy Privium Fund Management B.V.                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Statement_Regarding_Principal_Adverse_Impacts.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Statement regarding Principal Adverse Impacts                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Integration_of_sustainability_risks.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Integration of sustainability risks                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-3\">\n            <h3>Financial Reports Fund Manager<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/privium-amsterdam\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      (Semi) Annual Financial Reports via website van Privium Fund Management BV                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section cta-section\">\n  <div class=\"container cta-content\">\n    <div class=\"reveal\">\n              <h2>Klaar om te investeren in de toekomst van gezondheidszorg?<\/h2>\n                    <p>Neem contact op voor een persoonlijk gesprek of schrijf u in voor onze nieuwsbrief.<\/p>\n          <\/div>\n    <div class=\"cta-actions reveal reveal-delay-1\">\n              <a href=\"https:\/\/aescap.pipedrive.com\/scheduler\/wOYYEktD\/intro-meeting-aescap\" class=\"btn-primary\" target=\"_blank\">\n          Plan een kennismaking          <span class=\"arrow\">&rarr;<\/span>\n        <\/a>\n                    <a href=\"#\" class=\"btn-cta-outline\" >\n          <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z\"\/><polyline points=\"22,6 12,13 2,6\"\/><\/svg>\n          Schrijf in voor nieuwsbrief        <\/a>\n          <\/div>\n  <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-857","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aescap Genetics Fonds - Aescap<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aescap Genetics Fonds - Aescap\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/\" \/>\n<meta property=\"og:site_name\" content=\"Aescap\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T13:59:22+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-genetics-fonds\\\/\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-genetics-fonds\\\/\",\"name\":\"Aescap Genetics Fonds - Aescap\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#website\"},\"datePublished\":\"2026-03-30T14:55:45+00:00\",\"dateModified\":\"2026-05-05T13:59:22+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-genetics-fonds\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#website\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/\",\"name\":\"Aescap\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.aescap.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#organization\",\"name\":\"Aescap\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/cropped-logo2021_restyle_180.png\",\"contentUrl\":\"https:\\\/\\\/www.aescap.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/cropped-logo2021_restyle_180.png\",\"width\":180,\"height\":121,\"caption\":\"Aescap\"},\"image\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aescap Genetics Fonds - Aescap","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/","og_locale":"nl_NL","og_type":"article","og_title":"Aescap Genetics Fonds - Aescap","og_url":"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/","og_site_name":"Aescap","article_modified_time":"2026-05-05T13:59:22+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/","url":"https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/","name":"Aescap Genetics Fonds - Aescap","isPartOf":{"@id":"https:\/\/www.aescap.com\/#website"},"datePublished":"2026-03-30T14:55:45+00:00","dateModified":"2026-05-05T13:59:22+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.aescap.com\/nl\/aescap-genetics-fonds\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.aescap.com\/#website","url":"https:\/\/www.aescap.com\/","name":"Aescap","description":"","publisher":{"@id":"https:\/\/www.aescap.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.aescap.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.aescap.com\/#organization","name":"Aescap","url":"https:\/\/www.aescap.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.aescap.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/02\/cropped-logo2021_restyle_180.png","contentUrl":"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/02\/cropped-logo2021_restyle_180.png","width":180,"height":121,"caption":"Aescap"},"image":{"@id":"https:\/\/www.aescap.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/comments?post=857"}],"version-history":[{"count":46,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/857\/revisions"}],"predecessor-version":[{"id":1683,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/857\/revisions\/1683"}],"wp:attachment":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/media?parent=857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}